These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 8559353)

  • 1. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome.
    Bril V; Ilse WK; Pearce R; Dhanani A; Sutton D; Kong K
    Neurology; 1996 Jan; 46(1):100-3. PubMed ID: 8559353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group.
    Lancet; 1997 Jan; 349(9047):225-30. PubMed ID: 9014908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High dose intravenous immune globulins and plasma exchange in Guillain-Barré Syndrome.
    Ravasio A; Pasquinelli M; Currò Dossi B; Neri W; Guidi C; Gessaroli M; Rasi F; Fabbri R; Mazzini G; Rebucci GG
    Ital J Neurol Sci; 1995 Oct; 16(7):487-92. PubMed ID: 8749707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of Guillain-Barré syndrome with high-dose intravenous immunoglobulins--a comparison with plasma exchange].
    Kamei T; Nakagawa H; Uchiyama F; Fukuyama J
    Rinsho Shinkeigaku; 1993 Jun; 33(6):660-2. PubMed ID: 8403689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma exchange versus intravenous immunoglobulin for Guillain-Barré syndrome.
    Hughes RA
    Ther Apher; 1997 May; 1(2):129-30. PubMed ID: 10225757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison between IVIg and plasma exchange in Guillain-Barré syndrome: a review and decision analysis of the two treatment modalities.
    Dawson WB; Phillips LH
    Clin Neuropharmacol; 1995 Oct; 18(5):377-90. PubMed ID: 8665552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment related fluctuations in Guillain-Barré syndrome after high-dose immunoglobulins or plasma-exchange.
    Kleyweg RP; van der Meché FG
    J Neurol Neurosurg Psychiatry; 1991 Nov; 54(11):957-60. PubMed ID: 1800666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous immunoglobulin treatment in children with Guillain-Barre syndrome.
    Gürses N; Uysal S; Cetinkaya F; Işlek I; Kalayci AG
    Scand J Infect Dis; 1995; 27(3):241-3. PubMed ID: 8539548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Value of intravenous immunoglobulins. A case of Guillain-Barré syndrome].
    Hidou M; Olivier J; Vivant JF
    Rev Neurol (Paris); 1992; 148(11):706-8. PubMed ID: 1303562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second response to immunoglobulin in recurrent Guillain-Barré syndrome.
    Nagappan R; Barker J
    N Z Med J; 1998 Nov; 111(1077):433-4. PubMed ID: 9861925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Guillain-Barré syndrome with intravenous immunoglobulin.
    Sater RA; Rostami A
    Neurology; 1998 Dec; 51(6 Suppl 5):S9-15. PubMed ID: 9851724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Efficacy of Intravenous Immunoglobulin in Guillain-Barré Syndrome: The Experience of a Tertiary Medical Center.
    Shalem D; Shemer A; Shovman O; Shoenfeld Y; Kivity S
    Isr Med Assoc J; 2018 Dec; 20(12):754-760. PubMed ID: 30550005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Guillain-Barré syndrome: plasma exchange or immunoglobulins intravenously?
    van der Meché FG
    Ann Med Interne (Paris); 1994; 145(5):293-5. PubMed ID: 7985934
    [No Abstract]   [Full Text] [Related]  

  • 14. Sequential treatment of Guillain-Barré syndrome with extracorporeal elimination and intravenous immunoglobulin.
    Haupt WF; Rosenow F; van der Ven C; Borberg H; Pawlik G
    J Neurol Sci; 1996 May; 137(2):145-9. PubMed ID: 8782169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Italian Guillain-Barré Study Group. The prognosis and main prognostic indicators of Guillain-Barré syndrome: a multicentre prospective study of 297 patients.
    Hughes RA; Hadden RD; Rees JH; Swan AV
    Brain; 1998 Apr; 121 ( Pt 4)():767-9. PubMed ID: 9577400
    [No Abstract]   [Full Text] [Related]  

  • 16. Intravenous immune globulins in patients with Guillain-Barré syndrome and contraindications to plasma exchange: 3 days versus 6 days.
    Raphael JC; Chevret S; Harboun M; Jars-Guincestre MC;
    J Neurol Neurosurg Psychiatry; 2001 Aug; 71(2):235-8. PubMed ID: 11459901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous immunoglobulin in two children with Guillain-Barré syndrome.
    Notarangelo LD; Duse M; Tiberti S; Guarneri B; Brunori A; Negrini A; Ugazio AG
    Eur J Pediatr; 1993 Apr; 152(4):372-4. PubMed ID: 8482293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group.
    van der Meché FG; Schmitz PI
    N Engl J Med; 1992 Apr; 326(17):1123-9. PubMed ID: 1552913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma exchange and i.v.-immunoglobulins: new approaches to the treatment of Guillain-Barre' syndrome.
    Fasanaro AM; Pizza V; Stella L
    Acta Neurol (Napoli); 1992; 14(4-6):369-80. PubMed ID: 1293980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relapses in the Guillain-Barré syndrome after treatment with intravenous immune globulin or plasma exchange.
    Romano JG; Rotta FT; Potter P; Rosenfeld V; Santibanez R; Rocha B; Bradley WG
    Muscle Nerve; 1998 Oct; 21(10):1327-30. PubMed ID: 9736064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.